| abstract |
The present invention relates to a) poxvirus vectors encoding at least human papillomavirus (HPV) E6 and E7 polypeptides and immunostimulatory cytokines, and b) anti-PD-L1 antibodies or antigen binding thereof for use in the treatment of HPV-positive cancers A combination of fragments, wherein the first administration of the poxvirus is performed 5 to 10 days before the first administration of the anti-PD-L1 antibody, followed by the administration of the poxvirus and the anti-PD-L1 antibody. |